Le Lézard
Classified in: Health
Subjects: CCA, FVT

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024


Conference Call and Webcast to Follow

WASHINGTON, April 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, May 8, 2024, during which management will discuss the first quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 2594340.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, May 8, 2024, beginning at 8:30 PM ET and will be accessible until Wednesday, May 15, 2024, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 2594340.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact: 
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer 
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected] 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]

SOURCE Vanda Pharmaceuticals Inc.


These press releases may also interest you

at 20:23
Fluence Launches Generative AI Tools for Psychedelic Therapist Training
Fluence, a global leader in evidence-based psychedelic therapy training, has announced a partnership with Metamorph AI, a pioneering AI technology company, to develop an AI-powered tool to enhance the training of psychedelic therapists. We believe...

at 18:30
Next Gen Diagnostics and Vanderbilt Report the Use of Whole Genome Sequencing to Detect Transmission of Infection in a Neonatal Intensive Care Unit
Next Gen Diagnostics (NGD) and a team at Vanderbilt University Medical Center (VUMC) today announced the results of a study reporting that comparison of the whole genome sequence (WGS) of bacterial pathogens obtained from surveillance of infants in a...

at 17:21
Community Healthcare Trust Releases Inaugural Corporate Sustainability Report
Community Healthcare Trust Incorporated (the "Company") today announced the release of its inaugural Corporate Sustainability Report for the year 2023. This comprehensive report highlights the Company's commitment to environmental stewardship,...

at 17:14
The Rehabilitation Institute of St. Louis - West County, a 40-bed inpatient rehabilitation hospital, now open in Ballwin, Missouri
BJC HealthCare, one of the largest nonprofit health care organizations in the United States, and Encompass Health , the nation's largest owner and operator of inpatient rehabilitation hospitals, announce the opening of The Rehabilitation Institute of...

at 17:04
Cano Health Announces Agreement with Unsecured Creditors Committee and Court Approval of Disclosure Statement for its Reorganization Plan
Cano Health, Inc. ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced a global agreement with the Unsecured Creditors Committee representing the interests of the Company's...

at 17:00
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals...

More news about Health...


News published on and distributed by: